BRPI0309579B8 - composto com efeito antiandrogênico - Google Patents

composto com efeito antiandrogênico

Info

Publication number
BRPI0309579B8
BRPI0309579B8 BRPI0309579A BR0309579A BRPI0309579B8 BR PI0309579 B8 BRPI0309579 B8 BR PI0309579B8 BR PI0309579 A BRPI0309579 A BR PI0309579A BR 0309579 A BR0309579 A BR 0309579A BR PI0309579 B8 BRPI0309579 B8 BR PI0309579B8
Authority
BR
Brazil
Prior art keywords
compound
formula
antiandrogenic effect
treatment
antiandrogenic
Prior art date
Application number
BRPI0309579A
Other languages
English (en)
Other versions
BR0309579B1 (pt
BR0309579A (pt
Inventor
Theodor Kraemer Karl
Nietsch Karl-Heinz
Schaefer-Korting Monika
Pooth Rainer
Muenster Uwe
Mehnert Wolfgang
Original Assignee
Aventis Pharma Deutschland Gmbh
Aventis Pharma Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Aventis Pharma Deutschland Gmbh, Aventis Pharma Sa filed Critical Aventis Pharma Deutschland Gmbh
Publication of BR0309579A publication Critical patent/BR0309579A/pt
Publication of BR0309579B1 publication Critical patent/BR0309579B1/pt
Publication of BRPI0309579B8 publication Critical patent/BRPI0309579B8/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00—Preparations for care of the skin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/49—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds
    • A61K8/494—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds with more than one nitrogen as the only hetero atom
    • A61K8/4946—Imidazoles or their condensed derivatives, e.g. benzimidazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/08—Antiseborrheics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/10—Anti-acne agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/14—Drugs for dermatological disorders for baldness or alopecia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/66—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D233/72—Two oxygen atoms, e.g. hydantoin
    • C07D233/76—Two oxygen atoms, e.g. hydantoin with substituted hydrocarbon radicals attached to the third ring carbon atom
    • C07D233/78—Radicals substituted by oxygen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q7/00—Preparations for affecting hair growth
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q7/00—Preparations for affecting hair growth
    • A61Q7/02—Preparations for inhibiting or slowing hair growth

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Dermatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Birds (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Cosmetics (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

"preparações para a aplicação tópica de substâncias com efeito antiandrogênico". a presente invenção refere-se a um preparado, contendo pelo menos uma forma das nanopartículas de lipídios ou uma nanoemulsão, contendo pelo menos um composto da fórmula (i) e/ou uma forma estereoisômera do composto da fórmula (i) e/ou um sal fisiologicamente compatível do composto da fórmula (i), na qual r1 representa -(c~ 5~-c~ 17~)-alquila ou -(c~ 5~-c~17~)-alquenila, presta-se para o tratamento da alopécia androgenética, do hirsutismo, isto é, para evitar a penugem indesejada e para o tratamento da seborréia e acne e pode ser empregado além disso, na cosmética.
BRPI0309579A 2002-04-27 2003-04-14 composto com efeito antiandrogênico BRPI0309579B8 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
DE10218963.3 2002-04-27
DE10218963A DE10218963A1 (de) 2002-04-27 2002-04-27 Zubereitungen zur topischen Applikation von antiandrogen wirksamen Substanzen
PCT/EP2003/003837 WO2003093243A1 (de) 2002-04-27 2003-04-14 Zubereitungen zur topischen applikation von antiandrogen wirksamen substanzen

Publications (3)

Publication Number Publication Date
BR0309579A BR0309579A (pt) 2005-03-01
BR0309579B1 BR0309579B1 (pt) 2014-10-07
BRPI0309579B8 true BRPI0309579B8 (pt) 2021-05-25

Family

ID=29264882

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0309579A BRPI0309579B8 (pt) 2002-04-27 2003-04-14 composto com efeito antiandrogênico

Country Status (17)

Country Link
EP (1) EP1501806B1 (pt)
JP (1) JP4633459B2 (pt)
AR (1) AR039662A1 (pt)
AT (1) ATE321756T1 (pt)
AU (1) AU2003229658B2 (pt)
BR (1) BRPI0309579B8 (pt)
CA (1) CA2483786C (pt)
DE (2) DE10218963A1 (pt)
DK (1) DK1501806T3 (pt)
ES (1) ES2256735T3 (pt)
IL (1) IL164814A0 (pt)
MX (1) MXPA04009571A (pt)
MY (1) MY129714A (pt)
PE (1) PE20031044A1 (pt)
PT (1) PT1501806E (pt)
TW (1) TWI285637B (pt)
WO (1) WO2003093243A1 (pt)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1634874A4 (en) 2003-06-12 2008-04-02 Chugai Pharmaceutical Co Ltd imidazolidine
WO2005060661A2 (en) 2003-12-19 2005-07-07 The Regents Of The University Of California Methods and materials for assessing prostate cancer therapies
CA2554696C (en) * 2004-02-13 2009-06-30 Warner-Lambert Company Llc Androgen receptor modulators
CN100475781C (zh) * 2004-02-13 2009-04-08 沃尼尔·朗伯有限责任公司 雄激素受体调节剂
US7718684B2 (en) 2004-02-24 2010-05-18 The Regents Of The University Of California Methods and materials for assessing prostate cancer therapies and compounds
WO2005100305A1 (en) 2004-04-13 2005-10-27 Warner-Lambert Company Llc Androgen modulators
CA2562672C (en) 2004-04-22 2009-09-29 Warner-Lambert Company Llc 4-cyano-phenoxy derivatives as androgen modulators
WO2006006065A1 (en) * 2004-07-08 2006-01-19 Warner-Lambert Company Llc Androgen modulators
BRPI0514706A (pt) * 2004-08-31 2008-06-24 Warner Lambert Co moduladores de androgênio
TW200724139A (en) 2005-05-05 2007-07-01 Warner Lambert Co Androgen modulators
US7709517B2 (en) 2005-05-13 2010-05-04 The Regents Of The University Of California Diarylhydantoin compounds
PT3412290T (pt) 2006-03-27 2021-04-19 Univ California Modulador do recetor de androgénios para o tratamento de cancro da próstata e doenças associadas ao recetor de androgénios
JP5350217B2 (ja) 2006-03-29 2013-11-27 ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア ジアリールチオヒダントイン化合物
CA2966280A1 (en) 2007-10-26 2009-04-30 The Regents Of The University Of California Diarylhydantoin compounds
EA028869B1 (ru) 2010-02-16 2018-01-31 Арагон Фармасьютикалс, Инк. Модуляторы рецептора андрогенов и их применение
RU2503446C2 (ru) * 2012-02-07 2014-01-10 Алексей Валентинович Одинцов Средство для роста волос (варианты) и способ лечения облысения
NZ745682A (en) 2012-09-26 2019-09-27 Aragon Pharmaceuticals Inc Anti-androgens for the treatment of non-metastatic castrate-resistant prostate cancer
PL222631B1 (pl) * 2012-11-14 2016-08-31 Gdański Univ Medyczny Kompozycja farmaceutyczna zawierająca roksytromycynę, sposób jej wytwarzania oraz zastosowanie medyczne tej kompozycji i produkt leczniczy zawierający kompozycję
WO2014078929A1 (pt) * 2012-11-26 2014-05-30 Universidade Federal De Minas Gerais - Ufmg Formulações tópicas para a prevenção e tratamento da alopecia e para inibição do crescimento de pêlos
JOP20200097A1 (ar) 2013-01-15 2017-06-16 Aragon Pharmaceuticals Inc معدل مستقبل أندروجين واستخداماته
CN103965112A (zh) * 2014-05-13 2014-08-06 上海孚一生物科技有限公司 一种具有抗雄激素活性的化合物、制备方法及其应用
TWI726969B (zh) 2016-01-11 2021-05-11 比利時商健生藥品公司 用作雄性激素受體拮抗劑之經取代之硫尿囊素衍生物
CN111479560A (zh) 2017-10-16 2020-07-31 阿拉贡药品公司 用于治疗非转移性去势难治性前列腺癌的抗雄激素

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2693461B1 (fr) * 1992-07-08 1994-09-02 Roussel Uclaf Nouvelles phénylimidazolidines substituées, leur procédé de préparation, leur application comme médicaments et les compositions pharmaceutiques les renfermant.
US5411981A (en) * 1991-01-09 1995-05-02 Roussel Uclaf Phenylimidazolidines having antiandrogenic activity
FR2716110B1 (fr) * 1994-02-16 1996-04-05 Roussel Uclaf Compositions cosmétiques ou pharmaceutiques comprenant des liposomes.
AU726572B2 (en) * 1994-02-16 2000-11-09 Aventis Pharma S.A. Cosmetics or pharmaceutical compositions consisting of liposomes

Also Published As

Publication number Publication date
WO2003093243A1 (de) 2003-11-13
BR0309579B1 (pt) 2014-10-07
MY129714A (en) 2007-04-30
EP1501806B1 (de) 2006-03-29
PT1501806E (pt) 2006-06-30
DE50302818D1 (de) 2006-05-18
ES2256735T3 (es) 2006-07-16
JP2005535584A (ja) 2005-11-24
CA2483786A1 (en) 2003-11-13
AU2003229658A1 (en) 2003-11-17
PE20031044A1 (es) 2004-02-09
AR039662A1 (es) 2005-03-02
MXPA04009571A (es) 2005-01-11
CA2483786C (en) 2011-08-09
TW200407312A (en) 2004-05-16
JP4633459B2 (ja) 2011-02-16
ATE321756T1 (de) 2006-04-15
EP1501806A1 (de) 2005-02-02
DK1501806T3 (da) 2006-05-29
DE10218963A1 (de) 2003-11-20
TWI285637B (en) 2007-08-21
BR0309579A (pt) 2005-03-01
AU2003229658B2 (en) 2010-07-29
IL164814A0 (en) 2005-12-18

Similar Documents

Publication Publication Date Title
BRPI0309579B8 (pt) composto com efeito antiandrogênico
US6955816B2 (en) Anti-aging skin care composition and uses thereof
US8895037B2 (en) Administation of ellagic acid for the treatment of canities
US20040241114A1 (en) Hair Care and Nail Care Compositions Based on Ion-Pair Delivery System for Gender and Ethnic Selective Applications
JP2012184253A (ja) ざ瘡を治療するための組成物及び方法
ITMI20000630A1 (it) Impiego del resveratrolo per il trattamento di eczema disquamativo anche e psoriasi
WO2004010968A1 (en) Non-amphoteric glutathione derivative compositions for topical application
BR0311154A (pt) Composição para melhorar o melasma e composição para reduzir a opacidade da pele
BR102017003313B1 (pt) Composição anticaspa e método para a prevenção, redução ou tratamento da caspa
CA2411058C (en) Skin treatment using a new retinoid
BR9911833A (pt) Compostos diaril selenetos, composição farmacêutica, cosmética e sua utilização em medicina humana e veterinária, bem como em cosmetologia
ES2494928T3 (es) Composición que comprende polisacáridos mucilaginosos derivados de Aloe barbadensis combinados con liposomas, procedimiento para la obtención de los mismos y su uso como protector solar, un agente antiacné, un regenerador epidérmico y un hidratante
KR930703252A (ko) 항알레르기성 화장품 또는 약학적, 특히 피부학적 조성물의 제조에 사용되는 쿠쿠르비틴의 용도 및 그의 사용방법
WO2008041608A1 (fr) Préparation externe cutanée et produit de soin capillaire
JP2004149424A (ja) 化粧料及び化粧料の保湿機能改善方法
BR102017003319B1 (pt) Complexo seborregulador, composição tópica, uso de um complexo seborregulador e método de tratamento da acne ou da caspa
ITMI970339A1 (it) Formulazioni farmaceutiche contenenti colostro e uso del colostro per il trattamento della caduta dei capelli
US6399085B1 (en) Method of moisturizing the skin by the topical application of Δ5-androstene-3β-ol-7,17 dione and metabolizable precursors thereof
ES2897401T3 (es) Composición que comprende un antiséptico, un neutralizador de compuestos sulfurados volátiles y un agente anticariogénico
JP2011098901A (ja) アクネ用皮膚外用剤
BR0105926A (pt) Composição cosmética ou farmacêutica útil na inibição ou retardamento de alopecia humana por meio de aplicação tópica da composição
US20230018283A1 (en) Hair growth compositions
ES2162113T3 (es) Metodo de tratamiento cosmetico del cabello.
ES1306968U (es) Complejo nutricional capilar.
WO2012154903A1 (en) Compositions containing extracts of mucor miehei and mucor rouxii

Legal Events

Date Code Title Description
B25A Requested transfer of rights approved

Owner name: AVENTIS PHARMA S.A. (FR)

Free format text: TRANSFERIDO DE: AVENTIS PHARMA DEUTSCHLAND GMBH

B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B15K Others concerning applications: alteration of classification

Free format text: PARA INT.CL: C07D 233/78, A61K 31/4166, A61P 15/00

Ipc: C07D 233/78 (2011.01), A61K 31/4166 (2011.01)

B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]

Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI

B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 10 (DEZ) ANOS CONTADOS A PARTIR DE 07/10/2014, OBSERVADAS AS CONDICOES LEGAIS.

B16C Correction of notification of the grant [chapter 16.3 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 14/04/2003 OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF

B21A Patent or certificate of addition expired [chapter 21.1 patent gazette]

Free format text: PATENTE EXTINTA EM 14/04/2023